Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Germany
  4. Deutsche Boerse AG
  5. MPH Health Care AG
  6. Ratings
    93M1   DE000A289V03

MPH HEALTH CARE AG

(93M1)
  Report
Real-time Estimate Quote. Real-time Estimate Tradegate - 07/30 03:30:00 am
27.05 EUR   -0.92%
06/11ORIGINAL-RESEARCH : MPH Health Care AG (von First Berlin Equity Research GmbH): Buy
DJ
06/02PRESS RELEASE : MPH Health Care AG: result Q1-2021
DJ
06/02MPH HEALTH CARE AG : result Q1-2021
EQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Investment
Trading -
ESG Refinitiv -
Financials
Sales Growth
Growth rating is based on the evolution of the turnover of the company between the last year and the three coming years according to consensus estimates
Earnings Growth -
EBITDA / Sales -
Profitability
Profitability rating is based on net margin of the company for the current year and the next one according to consensus estimates
Finances
Finances rating is based on the evolution of the net debt of the company (debt or cash) and its Ebitda, compared to its revenue
-
Valuation
P/E ratio
Price Earnings Ratio rating compared the companyĺs current share price to its per-share earnings for the current fiscal year and the next one
EV / Sales
Valuation rating is based on the ratio between enterprise value and its turnover for the current fiscal year and the next one
-
Price to Book -
Price to Free Cash Flow
Yield
"Yield" rating is based on the dividend relative to its share price
Momentum
Turnover review 12m
Revenue revisions (one year) rating is based on the evolution of revenue revisions of the company for the current fiscal year and the next one
Turnover review 4m
Revenue revisions (four months) rating is based on the evolution of revenue revisions of the company for the current fiscal year and the next one
Turnover review 7 days
Earnings revision 12m
EPS revisions (one year) rating is based on the evolution of EPS (earnings per share) revisions of the company for the current fiscal year and the next one
Earnings revision 4m
EPS revisions (four months) rating is based on the evolution of EPS (earnings per share) revisions of the company for the current fiscal year and the next one
Consensus
Analyst Opinion
Consensus rating is based on analyst recommendations
Potential Price Target
Potential rating is based on the average target price fixed by the consensus from Thomson Reuters
Price target revision 4m
Revision of opinion 4m
Revision of opinion 12m
Business Predictability
Analyst Coverage
Divergence of Estimates
Business Predictability rating is based on the dispersion of analysts' estimates on the evolution of the company business in the coming years (range estimates)
-
Divergence of analysts' opinions -
Divergence of Target Price
Earnings quality
Earnings quality rating is based on quality of past earnings released by the company compared to analysts' estimates
Technical analysis
Short Term Timing
Short Term Timing rating is defined according to the positioning of the last closed trading price, within the area between the short term support and resistance on the basis of technical analysis in daily data
-
Middle Term Timing
Mid-Term Timing rating is defined according to the positioning of the last closed trading price, within the area between the mid-term support and resistance on the basis of technical analysis in daily data
-
Long Term Timing
Long Term Timing rating is defined according to the positioning of the last closed trading price, within the area between the long term support and resistance on the basis of technical analysis in daily data
-
RSI
RSI rating is based on the ranking of the security in the panel studied according to the mathematical indicator RSI 14 period
-
Bollinger Spread
Bollinger Bands rating is based on the ranking of the security in the panel studied according to the spread of the Bollinger bands
-
Unusual Volumes
Abnormal Volumes rating is based on the ranking of the security in the panel studied according to volume of the last session compared to an average session
-
Summary
  • Overall, the company has poor fundamentals for a medium to long-term investment strategy.
Strengths
  • The prospective high growth for the next fiscal years is among the main assets of the company
  • This company will be of major interest to investors in search of a high dividend stock.
  • Over the last twelve months, the sales forecast has been frequently revised upwards.
  • Over the last 4 months, analysts have significantly revised upwards the company's estimated sales.
  • The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
  • Over the past twelve months, analysts' opinions have been strongly revised upwards.
  • The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.
Weaknesses
  • The company has insufficient levels of profitability.
  • With an expected P/E ratio at 28.8 and 61.21 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
  • For the past year, analysts have significantly revised downwards their profit estimates.
  • For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
  • Over the past four months, analysts' average price target has been revised downwards significantly.
  • The average consensus view of analysts covering the stock has deteriorated over the past four months.
Ratings chart - Surperformance
Sector Generic Pharmaceuticals
1st jan.Capitalisation (M$)Investor Rating
MPH HEALTH CARE AG19.74%139
SHANGHAI FOSUN PHARMACEUTIC..38.45%28 023
SUN PHARMACEUTICAL INDUSTRI..18.68%22 714
OTSUKA HOLDINGS CO., LTD.0.97%22 091
ONO PHARMACEUTICAL CO., LTD..-18.65%11 525
ZHEJIANG NHU COMPANY LTD.-5.58%10 583
CIPLA LIMITED7.70%9 593
CADILA HEALTHCARE LIMITED19.98%7 886
ASPEN PHARMACARE HOLDINGS L..44.11%5 648
CHINA MEDICAL SYSTEM HOLDIN..99.31%5 487
RICHTER GEDEON VEGYÉSZETI G..9.41%5 021
SHIJIAZHUANG YILING PHARMAC..-0.90%4 620
SHENZHEN SALUBRIS PHARMACEU..-4.27%4 609
TAISHO PHARMACEUTICAL HOLDI..-10.50%4 533
KRKA, D. D.19.26%4 040
SICHUAN KELUN PHARMACEUTICA..-8.08%3 922
More Results